mda-5:: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties

被引:522
作者
Kang, DC
Gopalkrishnan, RV
Wu, QP
Jankowsky, E
Pyle, AM
Fisher, PB
机构
[1] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA
关键词
D O I
10.1073/pnas.022637199
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Human melanoma cells can be reprogrammed to terminally differentiate and irreversibly lose proliferative capacity by appropriate pharmacological manipulation. Subtraction hybridization identified melanoma differentiation-associated gene-5 (mda-5) as a gene induced during differentiation, cancer reversion, and programmed cell death (apoptosis). This gene contains both a caspase recruitment domain and putative DExH group RNA helicase domains. Atypical helicase motifs of MDA-5 deviate from consensus sequences but are well conserved in a potentially new group of cloned and hypothetical proteins. mda-5 is an early response gene inducible by IFN and tumor necrosis factor-alpha, responding predominantly to IFN-beta. Protein kinase C activation by mezerein further augments mda-5 expression induced by IFN-beta. Expression of mda-5 is controlled transcriptionally by IFN-beta, and the MDA-5 protein localizes in the cytoplasm. mda-5 displays RNA-dependent ATPase activity, and ectopic expression of mda-5 in human melanoma cells inhibits colony formation. In these contexts, mda-5 may function as a mediator of IFN-induced growth inhibition and/or apoptosis. MDA-5 is a double-stranded RNA-dependent ATPase that contains both a caspase recruitment domain and RNA helicase motifs, with a confirmed association with growth and differentiation in human melanoma cells.
引用
收藏
页码:637 / 642
页数:6
相关论文
共 34 条
[1]  
Ausubel F.M., 1992, SHORT PROTOCOLS MOL, V2nd
[2]   Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway [J].
Balachandran, S ;
Roberts, PC ;
Kipperman, T ;
Bhalla, KN ;
Compans, RW ;
Archer, DR ;
Barber, GN .
JOURNAL OF VIROLOGY, 2000, 74 (03) :1513-1523
[3]   Role for a bidentate ribonuclease in the initiation step of RNA interference [J].
Bernstein, E ;
Caudy, AA ;
Hammond, SM ;
Hannon, GJ .
NATURE, 2001, 409 (6818) :363-366
[4]   Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment [J].
Chou, JJ ;
Matsuo, H ;
Duan, H ;
Wagner, G .
CELL, 1998, 94 (02) :171-180
[5]   EFFECTS OF COMBINED TREATMENT WITH INTERFERON AND MEZEREIN ON MELANOGENESIS AND GROWTH IN HUMAN-MELANOMA CELLS [J].
FISHER, PB ;
PRIGNOLI, DR ;
HERMO, H ;
WEINSTEIN, IB ;
PESTKA, S .
JOURNAL OF INTERFERON RESEARCH, 1985, 5 (01) :11-22
[6]   Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60) [J].
Freemerman, AJ ;
Vrana, JA ;
Tombes, RM ;
Jiang, H ;
Chellappan, SP ;
Fisher, PB ;
Grant, S .
LEUKEMIA, 1997, 11 (04) :504-513
[7]  
GARBE C, 1993, J INVEST DERMATOL, V100, pS239
[8]  
GARBE C, 1990, J INVEST DERMATOL, V95, P231
[9]   RECOMBINANT HUMAN INTERFERON SENSITIZES RESISTANT MYELOID LEUKEMIC-CELLS TO INDUCTION OF TERMINAL DIFFERENTIATION [J].
GRANT, S ;
BHALLA, K ;
WEINSTEIN, B ;
PESTKA, S ;
MILENO, MD ;
FISHER, PB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 130 (01) :379-388
[10]   MODULATION OF TUMOR ASSOCIATED ANTIGEN EXPRESSION AND SHEDDING BY RECOMBINANT HUMAN-LEUKOCYTE AND FIBROBLAST INTERFERONS [J].
GREINER, JW ;
SCHLOM, J ;
PESTKA, S ;
LANGER, JA ;
GIACOMINI, P ;
KUSAMA, M ;
FERRONE, S ;
FISHER, PB .
PHARMACOLOGY & THERAPEUTICS, 1985, 31 (03) :209-236